Categories: NewsPharmaceutical

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days.

Fireside Chat Details:
Event: Stifel 2023 Virtual Targeted Oncology Days
Date/Time: Wednesday, April 26th, 2023 at 11:00 AM ET

A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 30 days following the live event.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com.

Investor Contact:

Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com

Media Contact:

Loraine Spreen
Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

Staff

Recent Posts

ZEISS Vision Care US Names Healthcare Industry Veteran Gary Rosenblum as President and Chief Executive Officer

Most Recently Serving as President for Oticon, a Division of Demant, Rosenblum Brings 30+ Years…

2 hours ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for…

5 hours ago

As Dangerous US Heat Wave Intensifies, AccuWeather Urges Public to Rely on Science-Backed RealFeel® Temperature for Accurate Danger Index

AccuWeather's RealFeel® Temperature is the only authentic formula-based metric—unlike 'Feels Like,' which lacks scientific credibility.Request…

5 hours ago

New Data Signals IVD Growth in a Shifting Market Amid Tariff Uncertainty

Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis ARLINGTON,…

5 hours ago

Medmovie Hx Heart App Launch Elevates Health Literacy and Empowers Shared Decision Making for Cardiovascular Care

Digital tool equips healthcare providers with trusted visual content to simplify complex heart information at…

5 hours ago

Premera Blue Cross Blue Shield of Alaska Announces Actions to Simplify Prior Authorization Process

Blue Cross and Blue Shield companies aim to improve the prior authorization process to make…

5 hours ago